Deep Dive: Oncology 2021This has probably been the toughest year for oncology researchers in memory. As this issue’s contributors discuss, funding Share XDeep Dive: Oncology 2021https://pharmaphorum.com/views-analysis-oncology/deep-dive-oncology-2021/
ASCO21: Gilead sets up first FDA okay for CAR-T in adult ALL with Tecartus dataNovartis’ Kymriah has had the CAR-T therapy market for acute lymphoblastic leukaemia (ALL) to itself so far, but Share XASCO21: Gilead sets up first FDA okay for CAR-T in adult ALL with Tecartus datahttps://pharmaphorum.com/news/asco21-gilead-sets-up-first-fda-okay-for-adult-all-with-tecartus-data/
ASCO21: Lynparza aces adjuvant breast cancer therapy trialAstraZeneca and Merck & Co’s Lynparza is primed for even wider use in the treatment of breast cancer Share XASCO21: Lynparza aces adjuvant breast cancer therapy trialhttps://pharmaphorum.com/news/asco21-lynparza-aces-adjuvant-breast-cancer-therapy-trial/
ASCO21: Novartis’ prostate cancer radiotherapy extends survivalNovartis’ big investment in radiopharmaceuticals for cancer seems to have paid off, after lead candidate 177Lu-PSMA-617 helped men Share XASCO21: Novartis’ prostate cancer radiotherapy extends survivalhttps://pharmaphorum.com/news/asco21-novartis-prostate-cancer-radiotherapy-extends-survival/
